Schaper Benz & Wise Investment Counsel Inc. WI purchased a new position in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,285 shares of the biopharmaceutical company’s stock, valued at approximately $205,000.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its position in shares of Bristol-Myers Squibb by 3.3% during the 3rd quarter. Wellington Management Group LLP now owns 45,407,364 shares of the biopharmaceutical company’s stock valued at $2,686,754,000 after purchasing an additional 1,444,304 shares during the period. Geode Capital Management LLC boosted its stake in Bristol-Myers Squibb by 2.7% during the third quarter. Geode Capital Management LLC now owns 36,940,288 shares of the biopharmaceutical company’s stock valued at $2,179,937,000 after buying an additional 982,470 shares in the last quarter. Nordea Investment Management AB boosted its stake in Bristol-Myers Squibb by 20.8% during the fourth quarter. Nordea Investment Management AB now owns 18,130,455 shares of the biopharmaceutical company’s stock valued at $1,136,598,000 after buying an additional 3,124,811 shares in the last quarter. Invesco Ltd. boosted its stake in Bristol-Myers Squibb by 2.2% during the third quarter. Invesco Ltd. now owns 15,731,092 shares of the biopharmaceutical company’s stock valued at $930,809,000 after buying an additional 331,205 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Bristol-Myers Squibb by 9.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 12,808,859 shares of the biopharmaceutical company’s stock valued at $798,646,000 after buying an additional 1,130,892 shares in the last quarter. 73.07% of the stock is currently owned by institutional investors and hedge funds.
Shares of BMY traded down $0.50 during midday trading on Friday, reaching $75.80. 13,773,108 shares of the stock were exchanged, compared to its average volume of 14,853,342. Bristol-Myers Squibb has a 12-month low of $53.22 and a 12-month high of $78.17. The firm has a 50 day simple moving average of $74.15 and a 200-day simple moving average of $66.36. The company has a quick ratio of 1.23, a current ratio of 1.32 and a debt-to-equity ratio of 1.18. The company has a market cap of $161.38 billion, a price-to-earnings ratio of 26.88, a P/E/G ratio of 1.61 and a beta of 0.49.
The business also recently disclosed a quarterly dividend, which was paid on Monday, May 2nd. Stockholders of record on Friday, April 1st were issued a dividend of $0.54 per share. This represents a $2.16 dividend on an annualized basis and a dividend yield of 2.85%. The ex-dividend date was Thursday, March 31st. Bristol-Myers Squibb’s dividend payout ratio is 76.60%.
In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 24th. The stock was sold at an average price of $67.00, for a total value of $2,010,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Rupert Vessey sold 74,559 shares of the firm’s stock in a transaction that occurred on Wednesday, March 16th. The stock was sold at an average price of $69.25, for a total value of $5,163,210.75. The disclosure for this sale can be found here. In the last three months, insiders have sold 165,668 shares of company stock worth $11,459,888. 0.09% of the stock is currently owned by insiders.
Several brokerages recently weighed in on BMY. Truist Financial raised their target price on Bristol-Myers Squibb from $76.00 to $81.00 in a research note on Monday, May 2nd. Guggenheim upped their target price on Bristol-Myers Squibb from $72.00 to $80.00 in a report on Monday, May 2nd. StockNews.com initiated coverage on Bristol-Myers Squibb in a report on Thursday, March 31st. They set a “strong-buy” rating for the company. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company an “equal weight” rating in a report on Wednesday, March 2nd. Finally, Morgan Stanley reduced their target price on Bristol-Myers Squibb from $66.00 to $64.00 and set an “underweight” rating for the company in a report on Wednesday, April 6th. One analyst has rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Bristol-Myers Squibb has a consensus rating of “Buy” and a consensus price target of $71.33.
About Bristol-Myers Squibb (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.